Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 ...
Pfizer is by far the larger and better-established drugmaker. With a market cap of $156 billion, the pharmaceutical leader boasts a deep product portfolio across several therapeutic areas. Even with a ...
1mon
Moderna Vaccine
Read Moderna Vaccine latest news on The Economic Times. Moderna Vaccine updates, Moderna Vaccine videos & more.
Moderna reported positive Phase 3 results for its mRNA seasonal influenza vaccine candidate, mRNA-1010, showing stronger protection than the standard flu shot in a large adult study population.
April 24 (Reuters) - German biotech company CureVac sued Moderna in Delaware federal court on Friday, alleging that Moderna's COVID-19 vaccine Spikevax infringed CureVac patents related to ...
RSV and flu mRNA vaccines struggle with lower durability, higher side effects, and weak uptake, leading to program cuts and ...
March 3 (Reuters) - Moderna has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences, and Arbutus Biopharma up to $2.25 billion to settle a long-running legal fight over the technology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results